A novel hypothesis‐generating computational workflow utilizing reverse pharmacophore mapping—A drug repurposing perspective of istradefylline towards major depressive disorder
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.17346 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Mietha Magdalena van der Walt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Human Metabolomics, Faculty of Natural and Agricultural Sciences, Potchefstroom Campus, North-West University, Potchefstroom, South Africa. Hauptthemen laut MEDLINE: Drug Repositioning, Major Depressive Disorder, Workflow, Antidepressive Agents. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Purpose Drug repurposing (DR) offers a compelling alternative to traditional drug discovery's lengthy, resource‐intensive process. DR is the process of identifying alternative clinical applications for pre‐approved drugs as a low‐risk and low‐cost strategy. Computational approaches are crucial during the early hypothesis‐generating stage of DR. However, ‘large‐scale’ data retrieval remains a significant challenge. A computational workflow addressing such limitations might improve hypothesis generation, ultimately benefit patients and advance DR research. Experimental Approach We introduce a novel computational workflow (combining free‐accessible computational platforms) to provide ‘proof‐of‐concept’ of the pre‐approved drug's suitability for repurposing. Three key phases are included: target fishing (via reverse pharmacophore mapping), target identification (via disease‐ and drug‐target pathway identification) and retrospective literature and drug‐like analysis (via in silico ADMET properties determination). Istradefylline is a Parkinson's disease‐approved drug with literature‐attributed antidepressant properties remaining unclear. Practically applied, istradefylline's antidepressant activity was assessed in the context of major depressive disorder (MDD). Key Results Data mining aided by target identification resulted in istradefylline potentially representing a novel antidepressant drug class. Retrieved drug targets (KYNU, MAO‐B, ALOX12 and PLCB2) associated with selected MDD pathways (tryptophan metabolism and serotonergic synapse) generated a hypothesis that istradefylline increased extracellular 5‐HT levels (MAO‐B inhibition) and reduced inflammation (KYNU, ALOX12 and PLCB2 inhibition). Conclusion and Implications The practically applied workflow's generated hypothesis aligns with known experimental data, validating the effectiveness of this novel computational workflow. It is a low‐risk and low‐cost DR computational tool providing a bird's‐eye view for exploring alternative clinical applications of pre‐approved drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Human Metabolomics, Faculty of Natural and Agricultural Sciences, Potchefstroom Campus, North-West University, Potchefstroom, South Africa.
ORCID-Profile: Mietha Magdalena van der Walt, Arnold Petrus Smith
Zitieren
APA
van der Walt, M. M., & Smith, A. P. (2025). A novel hypothesis‐generating computational workflow utilizing reverse pharmacophore mapping—A drug repurposing perspective of istradefylline towards major depressive disorder. British Journal of Pharmacology. https://doi.org/10.1111/bph.17346
Vancouver
van der Walt MM, Smith AP. A novel hypothesis‐generating computational workflow utilizing reverse pharmacophore mapping—A drug repurposing perspective of istradefylline towards major depressive disorder. British Journal of Pharmacology. 2025. doi:10.1111/bph.17346
BibTeX
@article{vanderWalt2025,
author = {van der Walt, Mietha Magdalena and Smith, Arnold Petrus},
title = {A novel hypothesis‐generating computational workflow utilizing reverse pharmacophore mapping—A drug repurposing perspective of istradefylline towards major depressive disorder},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.17346}
}
EUVIMED